NWPF

Search Results Tagged With medications

Medication

https://nwpf.org/wellness-center/treatment/medication/

Medicines used to treat Parkinson's disease include: Medicines for Movement Medicines for Non-motor Symptoms Medicines for movement fall into two categories: Anticholinergic Medicines (block…
February 25, 2014

Exenatide has Potential as a Disease Modifying Agent in Parkinson's Disease

https://nwpf.org/stay-informed/news/2014/05/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease/

A follow-up study of patients with Parkinson's disease (PD) who participated in an earlier "proof of concept" clinical trial using exenatide showed that improvements persisted twelve months after disc…
May 06, 2014

For Patients with Parkinson's Disease, Expensive Placebo Works Better

https://nwpf.org/stay-informed/news/2015/02/for-patients-with-parkinsons-disease,-expensive-placebo-works-better/

In a recent study, an "expensive" salt solution was shown to to be significantly more effective at managing the symptoms of patients with Parkinson's disease than an "inexpensive" one. The salt soluti…
February 01, 2015

Medicine and Cognition

https://nwpf.org/stay-informed/blog/2014/07/medicines-and-cognition/

Cognitive problems, namely executive dysfunction is common in Parkinson’s disease. Medicines, of course, can worsen cognition including memory. Although dopaminergic medicines are the most commonly us…
July 28, 2014

How Could I Be So Wrong?

https://nwpf.org/stay-informed/blog/2014/08/how-could-i-be-so-wrong/

It’s hard to avoid a bit of hysteria on being diagnosed with Parkinson’s Disease. To be scientifically rational and ruthlessly objective is hard even under the best circumstances. Nobody would confuse…
August 26, 2014

FDA lifts clinical hold on NeuroDerm's ND0612 to treat Parkinson's disease

https://nwpf.org/stay-informed/news/2015/05/fda-lifts-clinical-hold-on-neuroderms-nd0612-to-treat-parkinsons-disease/

The US Food and Drug Administration (FDA) has lifted the clinical hold on Israeli pharmaceutical firm NeuroDerm's US clinical studies of its primary product candidates, ND0612H and ND0612L, which are …
May 11, 2015

<< Back 1 - 6 of 6 Next >>